Kohei Shitara1, Eric Van Cutsem2, Yung-Jue Bang3, Charles Fuchs4, Lucjan Wyrwicz5, Keun-Wook Lee6, Iveta Kudaba7, Marcelo Garrido8, Hyun Cheol Chung9, Jeeyun Lee10, Hugo Raul Castro11, Wasat Mansoor12, Maria Ignez Braghiroli13, Nina Karaseva14, Christian Caglevic15,16, Luis Villanueva17, Eray Goekkurt18, Hironaga Satake19, Peter Enzinger20, Maria Alsina21, Al Benson22, Joseph Chao23, Andrew H Ko24, Zev A Wainberg25, Uma Kher26, Sukrut Shah26, S Peter Kang26, Josep Tabernero27. 1. National Cancer Center Hospital East, Kashiwa, Japan. 2. University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. 3. Seoul National University College of Medicine, Seoul, Korea. 4. Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut. 5. Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 6. Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 7. Latvian Oncology Center Rakus Gailezers, Riga, Latvia. 8. Pontifica Universidad Católica de Chile, Santiago, Chile. 9. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. 10. Samsung Medical Center, Seoul, Republic of Korea. 11. Grupo Medico Angeles, Guatemala City, Guatemala. 12. Christie Hospital NHS Trust, Manchester, United Kingdom. 13. Institute of Cancer of São Paolo, University of São Paolo, São Paolo, Brazil. 14. SPb SBHI Clinical Oncology, Dispensary, Russia. 15. Clinica Alemana Santiago, Universidad del Desarrollo, Santiago, Chile. 16. Currently at Cancer Research Department Fundación Arturo Lopez Perez, Santiago, Chile. 17. Hospital Clinico de la Universidad de Chile, Santiago, Chile. 18. Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, Germany. 19. Kobe City Medical Center General Hospital, Japan. 20. Dana-Farber Cancer Institute, Boston, Massachusetts. 21. Vall d'Hebron Institute of Oncology, Barcelona, Spain. 22. Northwestern Medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois. 23. City of Hope Comprehensive Cancer Center, Duarte, California. 24. University of California, San Francisco. 25. School of Medicine, University of California, Los Angeles. 26. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey. 27. Vall d'Hebron University Hospital (HUVH) and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
Abstract
Importance: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ cancer with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater. Design, Setting, and Participants: The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional trial enrolled 763 patients with untreated, locally advanced/unresectable or metastatic G/GEJ cancer with PD-L1 CPS of 1 or greater from 200 centers in 29 countries between September 18, 2015, and May 26, 2017. Interventions: Patients were randomized 1:1:1 to pembrolizumab 200 mg, pembrolizumab plus chemotherapy (cisplatin 80 mg/m2/d on day 1 plus fluorouracil 800 mg/m2/d on days 1 to 5 or capecitabine 1000 mg/m2 twice daily), or chemotherapy plus placebo, every 3 weeks. Main Outcomes and Measures: Primary end points were overall survival (OS) and progression-free survival (PFS) in patients with PD-L1 CPS of 1 or greater or 10 or greater. Results: A total of 763 patients were randomized to pembrolizumab (n = 256), pembrolizumab plus chemotherapy (n = 257), or chemotherapy (n = 250). The median (range) age of all patients in the study cohort was 62 (20-87) years; 554 of 763 (72.6%) were men. At final analysis, after a median (range) follow-up of 29.4 (22.0-41.3) months, pembrolizumab was noninferior to chemotherapy for OS in patients with CPS of 1 or greater (median, 10.6 vs 11.1 months; hazard ratio [HR], 0.91; 99.2% CI, 0.69-1.18). Pembrolizumab monotherapy was not superior to chemotherapy in patients with CPS of 1 or greater. Pembrolizumab prolonged OS vs chemotherapy in patients with CPS of 10 or greater (median, 17.4 vs 10.8 months; HR, 0.69; 95% CI, 0.49-0.97), but this difference was not statistically tested. Pembrolizumab plus chemotherapy was not superior to chemotherapy for OS in patients with CPS of 1 or greater (12.5 vs 11.1 months; HR, 0.85; 95% CI, 0.70-1.03; P = .05) or CPS of 10 or greater (12.3 vs 10.8 months; HR, 0.85; 95% CI, 0.62-1.17; P = .16) or for PFS in patients with CPS of 1 or greater (6.9 vs 6.4 months; HR, 0.84; 95% CI, 0.70-1.02; P = .04). Grade 3 to 5 treatment-related adverse event rates for pembrolizumab, pembrolizumab plus chemotherapy, and chemotherapy were 17%, 73%, and 69%, respectively. Conclusions and Relevance: This phase 3 randomized clinical trial found that among patients with untreated, advanced G/GEJ cancer, pembrolizumab was noninferior to chemotherapy, with fewer adverse events observed. Pembrolizumab or pembrolizumab plus chemotherapy was not superior to chemotherapy for the OS and PFS end points tested. Trial Registration: ClinicalTrials.gov Identifier: NCT02494583.
Importance: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ cancer with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater. Design, Setting, and Participants: The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional trial enrolled 763 patients with untreated, locally advanced/unresectable or metastatic G/GEJ cancer with PD-L1 CPS of 1 or greater from 200 centers in 29 countries between September 18, 2015, and May 26, 2017. Interventions: Patients were randomized 1:1:1 to pembrolizumab 200 mg, pembrolizumab plus chemotherapy (cisplatin 80 mg/m2/d on day 1 plus fluorouracil 800 mg/m2/d on days 1 to 5 or capecitabine 1000 mg/m2 twice daily), or chemotherapy plus placebo, every 3 weeks. Main Outcomes and Measures: Primary end points were overall survival (OS) and progression-free survival (PFS) in patients with PD-L1 CPS of 1 or greater or 10 or greater. Results: A total of 763 patients were randomized to pembrolizumab (n = 256), pembrolizumab plus chemotherapy (n = 257), or chemotherapy (n = 250). The median (range) age of all patients in the study cohort was 62 (20-87) years; 554 of 763 (72.6%) were men. At final analysis, after a median (range) follow-up of 29.4 (22.0-41.3) months, pembrolizumab was noninferior to chemotherapy for OS in patients with CPS of 1 or greater (median, 10.6 vs 11.1 months; hazard ratio [HR], 0.91; 99.2% CI, 0.69-1.18). Pembrolizumab monotherapy was not superior to chemotherapy in patients with CPS of 1 or greater. Pembrolizumab prolonged OS vs chemotherapy in patients with CPS of 10 or greater (median, 17.4 vs 10.8 months; HR, 0.69; 95% CI, 0.49-0.97), but this difference was not statistically tested. Pembrolizumab plus chemotherapy was not superior to chemotherapy for OS in patients with CPS of 1 or greater (12.5 vs 11.1 months; HR, 0.85; 95% CI, 0.70-1.03; P = .05) or CPS of 10 or greater (12.3 vs 10.8 months; HR, 0.85; 95% CI, 0.62-1.17; P = .16) or for PFS in patients with CPS of 1 or greater (6.9 vs 6.4 months; HR, 0.84; 95% CI, 0.70-1.02; P = .04). Grade 3 to 5 treatment-related adverse event rates for pembrolizumab, pembrolizumab plus chemotherapy, and chemotherapy were 17%, 73%, and 69%, respectively. Conclusions and Relevance: This phase 3 randomized clinical trial found that among patients with untreated, advanced G/GEJ cancer, pembrolizumab was noninferior to chemotherapy, with fewer adverse events observed. Pembrolizumab or pembrolizumab plus chemotherapy was not superior to chemotherapy for the OS and PFS end points tested. Trial Registration: ClinicalTrials.gov Identifier: NCT02494583.
Authors: Charles S Fuchs; Kohei Shitara; Maria Di Bartolomeo; Sara Lonardi; Salah-Eddin Al-Batran; Eric Van Cutsem; David H Ilson; Maria Alsina; Ian Chau; Jill Lacy; Michel Ducreux; Guillermo Ariel Mendez; Alejandro Molina Alavez; Daisuke Takahari; Wasat Mansoor; Peter C Enzinger; Vera Gorbounova; Zev A Wainberg; Susanna Hegewisch-Becker; David Ferry; Ji Lin; Roberto Carlesi; Mayukh Das; Manish A Shah Journal: Lancet Oncol Date: 2019-02-01 Impact factor: 41.316
Authors: Bernadett Szabados; Nick van Dijk; Yen Zhi Tang; Michiel S van der Heijden; Akhila Wimalasingham; Alfonso Gomez de Liano; Simon Chowdhury; Simon Hughes; Sarah Rudman; Mark Linch; Thomas Powles Journal: Eur Urol Date: 2017-09-13 Impact factor: 20.096
Authors: Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin Journal: N Engl J Med Date: 2017-02-17 Impact factor: 91.245
Authors: Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz Journal: Science Date: 2017-06-08 Impact factor: 47.728
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: Arnaud D Roth; Nicola Fazio; Roger Stupp; Stephen Falk; Jürg Bernhard; Piercarlo Saletti; Dieter Köberle; Markus M Borner; Kaspar Rufibach; Rudolf Maibach; Martin Wernli; Martin Leslie; Robert Glynne-Jones; Lukas Widmer; Matthew Seymour; Filippo de Braud Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Ching Ying Lin; Pareen Mehta; Kevin M Waters; Elena Chang; Andrew Hendifar; Arsen Osipov; Miguel Burch; De-Chen Lin; Alexandra Gangi; May Cho; Jun Gong Journal: AME Case Rep Date: 2021-07-25
Authors: Daniel V T Catenacci; Stephanie Moya; Samantha Lomnicki; Leah M Chase; Bryan F Peterson; Natalie Reizine; Lindsay Alpert; Namrata Setia; Shu-Yuan Xiao; John Hart; Uzma D Siddiqui; D Kyle Hogarth; Oliver S Eng; Kiran Turaga; Kevin Roggin; Mitchell C Posner; Paul Chang; Sunil Narula; Murtuza Rampurwala; Yuan Ji; Theodore Karrison; Chih-Yi Liao; Blase N Polite; Hedy L Kindler Journal: Cancer Discov Date: 2020-11-24 Impact factor: 39.397
Authors: Woosook Kim; Timothy H Chu; Henrik Nienhüser; Zhengyu Jiang; Armando Del Portillo; Helen E Remotti; Ruth A White; Yoku Hayakawa; Hiroyuki Tomita; James G Fox; Charles G Drake; Timothy C Wang Journal: Gastroenterology Date: 2020-10-29 Impact factor: 22.682